FK037 has potent therapeutic activity against lethal systemic infections and experimental local infections due to a wide variety of Gram-positive and Gram-negative bacteria such as staphylococci, Streptococcus pneumoniae, Enterobacteriaceae and Pseudomonas aeruginosa in mice. In murine systemic infections, FK037was the most effective of the cephalosporins and imipenem tested against highly methicillin-resistant Staphylococcus aureus (H-MRSA). It was more effective than ceftazidime against selected strains of S. aureus and Enterobacteriaceae, except Serratia marcescens and P. aeruginosa against which FK037was as effective as ceftazidime and was as effective as cefpirome against all organisms tested, except MRSA and P. aeruginosa against which FK037was more effective than cefpirome. These results correlated well with its in vitro activity. In murine local infections, with few exceptions, FK037 was more effective than ceftazidime and cefpirome against Klebsiella pneumonia in ED50values and against methicillin-sensitive S. aurens (MSSA) subcutaneous abscess, pyelonephritis with Staphylococcus epidermidis, E. coli and P. aeruginosa, intrauterine infections with S. aureus and E. coli in reducing the number of viable bacteria in the abscess, kidneys and uterus. It is noteworthy that the therapeutic effects of FK037 were more potent than had been anticipated from its in vitro activity against local infections with staphylococci and P. aeruginosa when compared with ceftazidime or cefpirome. In addition, the therapeutic effects of FK037were equipotent or superior to those of cefpirome and ceftazidime against pneumonia due to MSSA,K. pneumoniae and P. aeruginosa in reducing the number of viable bacteria in the lungs in mice using an in vivo pharmacokinetic model simulating human plasma concentrations after drip infusion of usual clinical doses (0.25 to 1.0g for MSSA, 0.063 to 0.125g for K. pneumoniae and 1.0 to 2.0 g for P. aeruginosa). FK037 induced an in vivo post-antibiotic effect (PAE) of3.4 hours against a thigh infection with MSSAin neutropenic mice. These results strongly suggest that it has potential for clinical use against various infections due to bacteria which include staphylococci and , P. aeruginosa.
FKO37,a new parenteral cephalosporin regarded as a so-called fourth generation cephalosporin, offers some advantages over the commercially available parenteral cephalosporins1\ It demonstrated extremely All these strains were previously screened for pathogenicity. These strains except MRSA and S. pneumoniae were passaged twice on a Trypticase soy agar (BBL) slant. MRSA was grownon Mueller-Hinton agar containing methicillin 3.13 /xg/ml at the first passage to avoid loss of methicillin resistance, followed by growth on the same agar mediumwithout the drug. S. pneumoniae was passaged twice in Mueller-Hinton broth (Difco) containing 5% horse serum for 15 hours.
Antibiotic Susceptibility Testing MICvalues were determined by the agar dilution method. Mueller-Hinton agar (Difco) was used for non-fastidious aerobic bacteria. This mediumsupplemented with 5% defibrinated horse blood was used for S. pneumoniae. The non-fastidious Gram-negative bacteria were precultured in Mueller-Hinton broth; P. aeruginosa 7001 were subcutaneously given drugs twice at post-infection 1 and 3 hours. The survival of the infected mice was observed for 3 to 5 days, and the 50% effective dose (ED50) was determined from the final survival rates by the Probit method2).
Pneumonia
Groups of 8 mice each were exposed to bacterial aerosol containing K. pneumoniae FP221 at 1.8 x 109cfu/ml in a chamberfor 20minutes. The infected mice were treated subcutaneously with 7 post-infection administrations (4, 24, 32, 48, 56, 72 and 80 hours) of serially diluted drugs. The ED50 was determined from the survival rates on post-infection day 7.
Subcutaneous Abscess
Groups of 7 male mice each were immunosuppressed with intraperitoneal cyclophosphamide at 200mg/kg. On the fourth day, the animals were inoculated subcutaneously with 0.1 ml of S. aureus 47 (4.6x l02cfu) on their dorsal regions. The infected mice were subcutaneously treated with 5 administrations of the drugs at post-infection 5, 24, 32, 48 and 56 hours at sites remote from the infection sites. Pieces of shaved skin at the infection sites were aseptically removedon post-infection day 3, and the viable bacteria were counted after homogenization by a conventional plating method.
Ascending Pyelonephritis
Ascending pyelonephritis was induced by the method of Obana4). Groups of each with 6 or 7 female mice aged for 4 or 5 weeks were deprived of drinking water overnight. Volumes of 0.1ml bacterial suspension of S. epidermidis 7022 (1.5x105cfu), E. coli 29 (2.4xl05cfu) or P aeruginosa 7001 (3.0x l05cfu) were inoculated into bladder of anesthetized mice through the urethra and the ureterostoma was closed with a clip for 5hours to prevent flux of bacteria. The infected mice were subcutaneously treated with the drugs for 5 times at post-infection 5, 24, 32, 48 and 56 hours. The kidneys were aseptically removed from the infected mice at post-infection day 3 and the viable bacteria in the kidneys were counted after homogenization by a conventional plating method. The detection limit of the viable bacteria was lOcfu per kidney in this model.
Intrauterine Infection Intrauterine infection was induced by the method of Obana5
). Groups of 6 female mice each, aged 4 or 5 weeks, were anesthetized prior to surgical exposure of their uteri. To prevent bacterial flux, the cervix was ligated with an operation suture, taking care not to ligate the arteries. A volume of 0.025ml of the bacterial suspension of S. aureus 47 (1.2 x 107cfu) or E. coli 22 (1.3 x 105cfu) was inoculated into the left uterine horns. The infected mice were treated subcutaneously with 5 administrations of the drugs at post-infection 5, 24, 32, 48 and 56 hours. The uterines were aseptically removed from the infected mice 3 days after infection, and the viable bacteria were counted after homogenization by a conventional plating method.
In Vivo Pharmacokinetic Model 1) Pneumonia: Groups of 5 male mice aged 4 weeks were immunosuppressed with 200mg/kg cyclophosphamide (ip) 4 days before infection. For K. pneumoniae FP221, the mice were exposed to bacterial aerosol at 2.4 x 109cfu/ml in a chamber for 20minutes. Volumes of 0.05ml each of the bacterial suspension of S. aureus 41r (2.2 x 107cfu) or P. aeruginosa 7001 (2.2 x 102cfu) in saline were intranasally inoculated in the anesthetized mice.
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2) Doses and dosage regimens: The doses and dosing schedules of the drugs were determined to approximate the time-related concentration in human plasma produced by usual clinical treatment of drip infusion with l.Og over a 1-hour period. The doses for drip infusion with 0.063, 0.125, 0.5 and 2.0g were calculated by multiplying each dose ratio with l.O g. Since drip infusion was impossible in mice and their plasma clearance was much faster than that of human, frequent subcutaneous injections at a 1-hour intervals were necessary. Humanplasma concentrations of FK037after l.O g drip-infusion were calculated from those after intravenous injection of 0.125g6). Those of cefpirome, ceftazidime and flomoxef were referred to data reported previously7~9). Sixteen hours after the inoculation of bacteria, the mice were treated with the drugs according to the above dosage regimens.
3) Measurement of bacterial count: Immediately before, 3, 6 and 24hours after the initial dosing, groups of 5 mice were sacrificed, and the lungs were aseptically removed. Each lung was homogenized and the number of viable bacteria was quantitated by a conventional plating method. The detection limit was lOcfu per lung.
In Vivo Post-antibiotic Effect (In Vivo PAE) In vivo PAEwas studied by the method of Gudmundsson10). Groups of 5 male mice each were immunosuppressed with intraperitoneal cyclophosphamide at 200 mg/kg and inoculated on the fourth day with 0.1 ml ofS. aureus 47 (2.2 x 106cfu) in the thigh of each mouse. Two hours later (time 0), a dose of 5 mg/kg of FK037 was subcutaneously injected in the treated groups. The infected mice were killed at selected intervals from -2 to 12hours. Thighs were aseptically removed, and the viable bacteria were counted after homogenization by a conventional plating method. The drug concentrations in the thighs infected with S. aureus 5027 after subcutaneous dosing of FK037 at 80mg/kg were determined by the disc-plate diffusion method using Morgarella morganii IFO 3848. The PAE was calculated by the following equation: PAE=T-C-M, where Mis the time thigh levels exceeded the MIC; T is the time required for a mean cfu/thigh of treated mice to increase to 1 log10 above the count at time M; and C is the time needed for the cfu/thigh of control animals to increase of 1 log10.
Statistical Analysis
The parallel line assay was used to determine the significant differences between FK037 and reference drugs in ED5Osfor lethal systemic infections. Tukey-type multiple comparison was used to determine the significant differences between the FK037-treated and reference drug-treated groups, and between the drug-treated and non-treated groups in log10 values of viable counts in local infections.
Results
Therapeutic Effects of FK037 on Lethal Systemic Infection The therapeutic effects of FK037against the 1 1 strains of 9 organisms were compared with those of the reference drugs (Table 1) . Against S. aureus 2550 (MSSA), FK037 was as effective as cefpirome and flomoxef, and was significantly more effective than ceftazidime and cefuzonam. Against 2 MRSAstrains, FK037 was the most effective of the drugs tested, including imipenem. Against S. pneumoniae FP1284, FK037was as effective as cefpirome and was significantly more effective than flomoxef and ceftizoxime. Against the Gram-negative bacteria, except S. marcescens and P. aeruginosa, the therapeutic activity of FK037was similar to that of cefpirome and was superior to each of ceftazidime, cefoperazone and flomoxef. These results correlated well with their MICvalues. Against S. marcescens 4003, FK037 was as effective as cefpirome and ceftazidime, and was moreeffective than cefoperazone and flomoxef. Against P. aeruginosa 7001, FK037was as effective as ceftazidime and elicited more potent effects than cefpirome and cefoperazone.
Therapeutic Effects of FK037on Pneumonia
The therapeutic effects of FK037on lethal pneumonia due to K. pneumoniae FP221 was compared JAN. 1993 a Mice were immunosuppressed by an intraperitoneal dose of 200mg/kg cyclophosphamide 4 days before challenge; bantibiotic was given subcutaneously 1 hour after challenge (c 1 and 3 hours after challenge); dagar dilution method (stamp method, 104cfu/spot, Mueller-Hinton agar); e statistical significances refer to parallel line assay for paired differences, significant difference from FK037 (P<0.05). 6.28d (2.73 -17.3 ) a Mice were exposed to bacterial aerosal containing K. pneumoniae FP221 at 1.8 x 109cfu/ml in a chamber for 20 minutes; b antibiotic was subcutaneously given 4, 24, 32, 48, 56, 72 and 80 hours after inhalation of bacteria; cagar dilution method (stamp method, 104cfu/spot, Mueller-Hinton agar); dstatistical significances refer to parallel line assay for paired differences, significant difference from FK037 (P < 0.05). with those of cefpirome, ceftazidime and flomoxef (Table  2 ). All non-treated control mice died on post-infection day 3 in this model. FK037 was as effective as cefpirome and more effective than ceftazidime and flomoxef and this finding which correlated well with their MICs.
Therapeutic Effects of FK037 on Subcutaneous Abscess
Against a subcutaneous abscess due to S. aureus 47 (MSSA), FK037 significantly decreased the viable cell counts in the skin to 5.91 and 2.03 log10 at the respective doses of 10 and lOOmg/kg when compared with 8.35 log10 in the control mice (Table 3 ). The therapeutic effect of FK037 was superior to that of ceftazidime which did not significantly decrease the viable cell counts, and this finding can be explained by the difference in their MICs. Although the MIC of FK037 was higher value than that of cefpirome and flomoxef, FK037at lOOmg/kgelicited an effect slightly superior to the two drugs since FK037decreased the viable cell counts about 10-fold more than the drugs.
Therapeutic Effects of FK037 on Ascending Pyelonephritis Against pyelonephritis with S. epidermidis 7022 (Table 4) , FK037 decreased the viable cell counts to 3 .75 log10 and significantly to 2.77 log10 in the kidneys at the respective doses of 10 and 50mg/kg respectively when compared with 6.01 log10 in the control mice. Although FK037 registered a higher JAN. 1993 MICvalue than those of cefpirome and flomoxef, FK037indicated an equipotent therapeutic effect to cefpirome and slightly superior to flomoxef which did not significantly decrease the viable cell counts at 50mg/kg. Against E. coli 29 (Table 5) , FK037 decreased the viable cell counts to 2.41 log10 at 0.5mg/kg when compared with 6.88 log10 in the control mice, and the infected kidneys in 2 of 6 mice were sterilized at 2.5mg/kg. The therapeutic effects of FK037 decreased the viable cell counts in the kidneys to 5.68 log10 and significantly to 2.72 log10 at the respective doses of 10 and 50mg/kg when compared with 8.78 log10 of the control mice. The therapeutic effects of FK037 were more potent than those of cefpirome and cefoperazone at both doses. Similarly, FK037elicited a slightly more potent effect than ceftazidime and cefpirome at 50mg/kg, although the MICof FK037was the same as that of ceftazidime.
Therapeutic Effects of FK037 on Intrauterine Infection Against intrauterine infection with S. aureus 47 (Table 7) , FK037 decreased the viable cell counts in the uterus to 6.03 log10 and significantly to 3.67 log10 at the respective doses of 5 and 20mg/kg when compared with 7.41 log10 of the control mice. The therapeutic effects of FK037 were equipotent to those a Immunosuppressed mice (cyclophosphamide, 200 mg/kg, ip, 4 days before inhalation) were exposed to bacterial aerosole of K. pneumoniae FP221 (2.4 x 109 cfu/ml) in a chamber for 20 minutes; b human plasma concentrations after drip infusion of antibiotic were reproduced in murine plasma; c mice were subcutaneously given 10 times with antibiotic at a 1-hour intervals 16 hours after inhalation; dagar dilution method (stamp method, 104cfu/spot, Mueller-Hinton agar); e statistical significances refer to Tukey-type multiple comparison for paired differences, significant difference (P < 0.05) from control, f significant difference (P< 0.05) from FK037. Dead a 0.05 ml bacterial suspension of P. aeruginosa 7001 (2.2 x 102 cfu) in saline was intranasally inoculated in the anesthetized immunosuppressed mice (cyclophosphamide, 200 mg/kg, ip, 4 days before inoculation); b human plasma concentrations after drip infusion of antibiotic were reproduced in murine plasma; cmice were subcutaneously given 10 times with antibiotic at a 1-hour intervals 16 hours after inoculation; dagar dilution method (stamp method, 104 cfu/spot, Mueller-Hinton agar); Statistical paired differences, significant difference (P < 0.05) from of cefpirome and were slightly superior to those of flornoxef, although its MIC value was higher than those of the two drugs. Against E. coli 22 (Table 8) of FK037were superior to those of cefpirome and ceftazidime which did not significantly decrease the viable cell counts at 0.5 mg/kg, and this result can be explained by the higher MICvalues of the latter.
Therapeutic Effects of FK037 in an In Vivo Pharmacokinetic Model The therapeutic effects of FK037on S. aureus 47 (MSSA) ( Table 9 ) were compared with those of cefpirome and flomoxef at doses equivalent to 0.25, 0.5 and l.Og in humans. FK037 exhibited dosedependent therapeutic effects although the viable counts in lungs from FK037-treated mice only at the dose equivalent to l.O g were significantly lower than those from control mice. The therapeutic effects of FK037were almost the same with those significances refer to Tukey-type multiple comparison for control, f significant difference (P< 0.05) from FK037. aIn vivo PAE was studied by the method of Gudmundsson10): b0.1 ml bacterial suspension of S. ctureus 47 (2.2 x 106 cfu) was inoculated in the thigh of mouse; cmice were immunosuppressed with intraperitoneal cyclophosphamide at 200 mg/kg 4 days before inoculation; d FK037 (5 mg/kg) was subcutaneously injected 2 hours after inoculation.
of cefpirome and flomoxef at all the doses tested. Against K. pneumoniae FP221 (Table 10) , the therapeutic effects of FK037were compared with those of cefpirome and ceftazidime at doses equivalent to 0.063 and 0.125 g in humans. The viable counts in the lungs from FK037-treated mice at both doses were significantly lower than those from the control mice at most sampling points and did not indicate any increases even 24hours after the initiation of dosing. The therapeutic effects of FK037were similar to those of cefpirome and more potent than those of ceftazidime at 0.063 g dose. Against P. aeruginosa 7001 (Table 1 1) , the therapeutic effects of FK037 were compared with those of cefpirome and ceftazidime at doses equivalent to 1.0 and 2.0g in humans. The viable counts in the lungs from FK037-treated mice at doses equivalent to 1.0 and 2.0g were significantly lower than those from the control mice 6 hours after the initation of dosing. All mice that had received FK037 which could not suppress the bacterial re-growth in the lungs, were still alive 24hours after the initiation of dosing, although all the control mice died. The therapeutic effects of FK037were similar to those of cefpirome and ceftazidime, although FK037 like cefpirome had a higher MIC than ceftazidime.
In Vivo Post-antibiotic Effect {In Vivo PAE) of FK037 As shown in Fig. 1, FK037 produced in vivo PAEof 3.4hours against a thigh infection with MSSA in neutropenic mice.
Discussion
The potent therapeutic activity of FK037against a wide range of bacteria, including S. aureus and P. aeruginosa, were confirmed in our present lethal systemic infection models in accord with its potent in vitro activity^. Against MRSA,it is noteworthy that FK037 indicated the highest activity of the tested drugs, including imipenem, in systemic infections. The detailed anti-MRSA activity of FK037 will be present in another paper11}. With regards to other bacteria, the therapeutic activity of FK037 correlated well with its in vitro activity when compared with that of the reference drugs. FK037 indicated pqtent activity similar to cefpirome, a so-called fourth-generation cephalosporin, against most organisms, but elicited a higher effect against MRSAand P. aeruginosa. Moreover, FK037 manifested a higher activity than ceftazidime against most organisms, except that its therapeutic activities against S. marcescensand P. aeruginosa were similar to those of ceftazidime. In addition to its effects against lethal systemic infections, FK037demonstrated potent therapeutic effects in several experimental local infections such as acute pneumonia due to K. pneumoniae, ascending pyelonephritis due to S. epidermidis, E. coli or P. aeruginosa, subcutaneous abscess due to S. aureus and intrauterine infections due to S. aureus or E. coli.
These results suggest that FK037 might be useful for treating various infections in patients. On comparison of its MICswith those of the reference drugs, FK037displayed excellent therapeutic effects as expected. However, in some infections due to staphylococci and P. aeruginosa, FK037 elicited effects more active than expected from its MICs. For instance, FK037indicated therapeutic effects which were either superior or similar to those of cefpirome and ceftazidime even its MICswere similar to or higher than those of *the latter drugs. These results might be due to higher bactericidal activity of FK037 at sub-MIC since the pharmacokinetic properties of these drugs are similar1'12). Against pneumonia with MSSA,K. pneumoniae or P! aeruginosa in an in vivo pharmacokinetic model in mice simulating human plasma concentrations, FK037was therapeutically effective at doses equivalent to probable clinical dose of 1.0g or less. Moreover, findings that the therapeutic effects of FK037were equipotent or superior to those of cefpirome, ceftazidime and flomoxef support its expected clinical potential.
In conclusion, FK037exhibited potent therapeutic effects on several experimental infections on the basis of its high antibacterial activity as a fourth-generation cephalosporin and displayed certain advantages over the reference drugs.
